Amundi’s Definium Therapeutics DFTX Stock Holding History

Amundi’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$662K	Sell	14,068 -68	-0.5%	-$1.68K	﹤0.01%	1542
2026 Q1	$267K	Buy	+14,136	New	+$240K	﹤0.01%	1786

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Amundi's DFTX Position: Q2 2026 in Review

Amundi reduced its Definium Therapeutics (DFTX) stake by 0.48% in Q2 2026, selling an estimated $1.68K and leaving 14,068 shares worth $662K. The position accounts for ﹤0.01% of the portfolio, ranked #1542.

Amundi first reported a position in DFTX in Q1 2026 and has held it in 2 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Amundi held 14,068 shares of Definium Therapeutics worth $662K as of Q2 2026.
Amundi sold 68 Definium Therapeutics shares in Q2 2026, an estimated $1.68K.
Definium Therapeutics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1542 holding.
Amundi first reported a position in Definium Therapeutics in Q1 2026 and has held it in 2 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.